A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

NCT04385563 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

338

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Metastatic Breast Cancer

Interventions

DRUG: TQ-B211
DRUG: Herceptin®
DRUG: docetaxel

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.